Welcome!

News Feed Item

CORRECTING and REPLACING MolecularHealth Guides Better Cancer Treatments with Two New Diagnostic Tests

Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:

MOLECULARHEALTH GUIDES BETTER CANCER TREATMENTS WITH TWO NEW DIAGNOSTIC TESTS

TreatmentMAP platform combines precision medicine with advanced data analytics to guide patients and physicians to the safest, most effective cancer treatment options

Backed by more than eight years of research and development, MolecularHealth announced today the official launch of TreatmentMAP™, its cancer treatment decision support offering. Based on a proprietary analytics engine, TreatmentMAP leverages the results of next generation sequencing (NGS) genetic tests to identify the optimal, safest treatment options for each individual patient. For the first time, cancer patients and their medical teams will have access to actionable information to guide the selection of targeted cancer treatments, presented in a clear and understandable way. TreatmentMAP became commercially available in Europe and the U.S. in April.

The company has two available versions of its offering:

  • TreatmentMAP Targeted Panel is the largest gene panel commercially available today, with over 500 genes that cover several thousand variants and have been determined to have the most clinical impact in cancer, and are therefore most likely to make a difference in treatment outcome.
  • TreatmentMAP Whole Exome, the first commercially available whole exome analysis for cancer, taking a comprehensive look at a patient’s genetic profile by examining the genes of both the tumor and germline.

Both testing options incorporate MolecularHealth’s SafetyMAP™, a proprietary identification of drug target safety or resistance effects, using the FDA’s Adverse Event Reporting Systems (AERS) as an input for analysis. Through MolecularHealth’s five-year research collaboration agreement with the FDA, MolecularHealth incorporates key data from AERS into SafetyMAP, providing the first drug safety analysis that combines adverse event information with molecular knowledge about drug activity within a patient. This ensures that treatment options will not only be effective, but won’t have unintended negative consequences for patients.

“I believe that the future of medicine lies in our ability to interpret seemingly disparate information,” said Lloyd Everson, M.D., co-CEO of MolecularHealth. “With the technology now at our disposal, there are mountains of data constantly being churned out of labs and clinical trials – but until recently, it was an unwieldy task to do anything productive with that information. TreatmentMAP allows us to pull in all of that data and make it truly usable.”

TreatmentMAP tests can be ordered in the United States and in Europe. In the U.S., a patient’s oncologist or pathologist sends a tumor sample to MolecularHealth’s CLIA-certified NGS lab in The Woodlands, Texas. Once the sample is sequenced, data on the tumor’s DNA, along with additional medical information on the patient, is fed into the company’s automated analytics platform. This platform cross-references patient-specific data with the latest peer-reviewed evidence, clinical trials, and other sources. A simple-to-understand report is delivered to the patient’s medical team, highlighting the treatment options that are most likely to be both effective and safe.

“We are still trying to understand cancer, and as an oncologist I have observed that the most effective cancer therapies are those that precisely target the unique biology of an individual patient's tumor,” said Joyce O’Shaughnessy, M.D., co-chair of breast cancer research at US Oncology and Baylor-Sammons Cancer Center. “TreatmentMAP offers new insights into the molecular drivers of a tumor, leading to expanded therapeutic options and greater chance for therapy response.”

“As a pathologist, I’m happy to have a company joining the molecular diagnostic space that’s more pathologist-friendly than some of the competition in this field,” said Thomas Wheeler, M.D., chairman of the Department of Pathology & Immunology at Baylor College of Medicine. “The market can only benefit from having more options to meet the needs of individual patients, and from what I’ve seen, MolecularHealth’s reports are not only more robust, but focus on the elements that are most important when determining a treatment path for a patient.”

Drs. O’Shaughnessy and Wheeler are members of the MolecularHealth advisory board.

For more information on TreatmentMAP and how to order a test, please visit MolecularHealth’s website.

ABOUT MOLECULARHEALTH

MolecularHealth is a leading biomedical company transforming molecular data into actionable clinical information for the most efficient and safest cancer treatment options for each individual cancer patient. By using advanced proprietary tumor analysis and interpretation to match patient-specific genetic and molecular test findings to the current state of the world’s biomedical knowledge about cancer, MolecularHealth provides doctors and patients with faster, more accurate insights into the role genes play in the progression and treatment of an individual’s cancer. Eight years in development by a multidisciplinary team of doctors, scientists and IT experts, MolecularHealth works in partnership with some of the world’s leading healthcare and information technology companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, and SAP AG. The company is headquartered in Heidelberg, Germany. U.S. headquarters, including a CLIA-certified NGS lab, are located in The Woodlands, Texas. The company also has offices in Boston, Mass.

Website: www.molecularhealth.com
Twitter: www.twitter.com/molecularhealth
LinkedIn: www.linkedin.com/company/molecularhealth
YouTube: www.youtube.com/user/MolecularHealthInc

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and G...
The current age of digital transformation means that IT organizations must adapt their toolset to cover all digital experiences, beyond just the end users’. Today’s businesses can no longer focus solely on the digital interactions they manage with employees or customers; they must now contend with non-traditional factors. Whether it's the power of brand to make or break a company, the need to monitor across all locations 24/7, or the ability to proactively resolve issues, companies must adapt to...
"DevOps is set to be one of the most profound disruptions to hit IT in decades," said Andi Mann. "It is a natural extension of cloud computing, and I have seen both firsthand and in independent research the fantastic results DevOps delivers. So I am excited to help the great team at @DevOpsSUMMIT and CloudEXPO tell the world how they can leverage this emerging disruptive trend."
You want to start your DevOps journey but where do you begin? Do you say DevOps loudly 5 times while looking in the mirror and it suddenly appears? Do you hire someone? Do you upskill your existing team? Here are some tips to help support your DevOps transformation. Conor Delanbanque has been involved with building & scaling teams in the DevOps space globally. He is the Head of DevOps Practice at MThree Consulting, a global technology consultancy. Conor founded the Future of DevOps Thought Leade...
DXWorldEXPO LLC announced today that ICC-USA, a computer systems integrator and server manufacturing company focused on developing products and product appliances, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City. ICC is a computer systems integrator and server manufacturing company focused on developing products and product appliances to meet a wide range of ...
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
DXWorldEXPO | CloudEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.
Everyone wants the rainbow - reduced IT costs, scalability, continuity, flexibility, manageability, and innovation. But in order to get to that collaboration rainbow, you need the cloud! In this presentation, we'll cover three areas: First - the rainbow of benefits from cloud collaboration. There are many different reasons why more and more companies and institutions are moving to the cloud. Benefits include: cost savings (reducing on-prem infrastructure, reducing data center foot print, redu...
Founded in 2000, Chetu Inc. is a global provider of customized software development solutions and IT staff augmentation services for software technology providers. By providing clients with unparalleled niche technology expertise and industry experience, Chetu has become the premiere long-term, back-end software development partner for start-ups, SMBs, and Fortune 500 companies. Chetu is headquartered in Plantation, Florida, with thirteen offices throughout the U.S. and abroad.
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term.
The technologies behind big data and cloud computing are converging quickly, offering businesses new capabilities for fast, easy, wide-ranging access to data. However, to capitalize on the cost-efficiencies and time-to-value opportunities of analytics in the cloud, big data and cloud technologies must be integrated and managed properly. Pythian's Director of Big Data and Data Science, Danil Zburivsky will explore: The main technology components and best practices being deployed to take advantage...
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...
CloudEXPO New York 2018, colocated with DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
SYS-CON Events announced today that DatacenterDynamics has been named “Media Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY. DatacenterDynamics is a brand of DCD Group, a global B2B media and publishing company that develops products to help senior professionals in the world's most ICT dependent organizations make risk-based infrastructure and capacity decisions.